NASDAQ · BDMDW

Baird Medical Investment Holdings Ltd.

$0.05 +$0.00 (+8.78%) 1D

Key Metrics

$994.41K
Market cap
P/E · TTM
$22.54M
Revenue · TTM
−$27.28M
Net income
EPS · TTM $-1.32
Dividend yield
Free cash flow −$1.39M
Beta · 1Y
EBITDA · TTM −$25.28M
Gross margin 83.8%

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 20.3 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Jun 15
    From its Mar 3 high, the share price fell 78%.

    Peak close $0.19 on Mar 3; trough close $0.04 on Jun 15. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -78%
  • Feb 20
    The stock moved +59.6% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Feb 20
  • Feb 17
    The stock moved +49.1% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Feb 17

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap
Enterprise value$9.54M
Shares outstanding
52-wk range$0.04 – $0.19
Avg volume · 20D38.9K
Net cash −$8.54M
Book value / share$1.52
ExchangeNASDAQ
About Baird Medical Investment Holdings Ltd.
IPO dateOct 2, 2024
Employees146

Baird Medical Investment Holdings Ltd is a specialized healthcare innovator dedicated exclusively to thyroid-related diseases and a microwave ablation (MWA) medical device manufacturer and provider in China.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S0.04
P/FCF
EV/EBITDA
EV/Sales0.42
Graham №

Profitability

Gross 83.8%
Operating -117.0%
Net -121.0%
FCF -6.2%
ROE / ROIC -76.8% · -69.0%

Financial Health

Current ratio1.70
Quick ratio1.66
Debt / equity0.28
Debt / EBITDA -0.35
Net cash −$8.54M
Working capital$22.61M

Cash Flow · TTM

Operating CF −$1.34M
Capex −$42.32K
Free cash flow −$1.39M
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

1 / 9
Weak fundamentals · 1 of 9 signals passing

Altman Z-Score

-0.5
Distress zone (< 1.81) · elevated risk

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2025-06-30 · computed by TickerWolf from SEC filings